Qiagen N.V. (BIT:1QGEN)
Italy · Delayed Price · Currency is EUR | Market Cap | 5.89B -26.8% |
| Revenue (ttm) | 1.82B +4.8% |
| Net Income | 348.80M +329.3% |
| EPS | 1.68 +338.2% |
| Shares Out | n/a |
| PE Ratio | 16.88 |
| Forward PE | 13.26 |
| Dividend | 2.18 (7.52%) |
| Ex-Dividend Date | Jan 8, 2026 |
| Volume | 12 |
| Average Volume | 295 |
| Open | 28.57 |
| Previous Close | 28.51 |
| Day's Range | 28.57 - 28.57 |
| 52-Week Range | 28.22 - 47.23 |
| Beta | 0.79 |
| RSI | 27.26 |
| Earnings Date | May 6, 2026 |
About Qiagen
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purif... [Read more]
Financial Performance
In 2025, Qiagen's revenue was $2.09 billion, an increase of 5.65% compared to the previous year's $1.98 billion. Earnings were $424.88 million, an increase of 408.28%.
Financial numbers in USD Financial StatementsNews
Qiagen price target lowered to $40 from $46 at TD Cowen
TD Cowen analyst Dan Brennan lowered the firm’s price target on Qiagen (QGEN) to $40 from $46 and keeps a Hold rating on the shares. The firm updated its model
Qiagen Transcript: Status update
Latent TB testing is a rapidly growing market with significant conversion potential from traditional skin tests. New innovations include faster, fully automated workflows and an AI tool for risk stratification, all exclusive to QuantiFERON. Customer feedback is strong, and the company remains confident in its 2028 financial targets.
QIAGEN Plans to Launch New Fully Automated Sample to Insight Workflow and an AI-Enabled Risk Stratification Tool to Advance QuantiFERON Latent TB Testing
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to advance its QuantiFERON latent tuberculosis (TB) test with a new...
Qiagen reports Q1 EPS 54c, consensus 54c
Reports Q1 revenue $492M, one estimate $499.2M. “QIAGEN (QGEN) made important progress across many areas of the portfolio in the first quarter, led by solid sales growth in Sample technologies,
QGEN Investors Have Opportunity to Join Qiagen N.V. Fraud Investigation with the Schall Law Firm
LOS ANGELES, May 06, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Qiagen N.V. (“Qiag...
QIAGEN Reports Full Results for Q1 2026
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today reports full results for the first quarter of 2026 in line with the preliminary ann...
Qiagen price target lowered to $43 from $54 at Deutsche Bank
Deutsche Bank analyst Jan Koch lowered the firm’s price target on Qiagen (QGEN) to $43 from $54 and keeps a Buy rating on the shares.
Qiagen price target lowered to EUR 34 from EUR 44 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Qiagen (QGEN) to EUR 34 from EUR 44 and keeps an Equal Weight rating on the shares.
Qiagen price target lowered to $45 from $60 at JPMorgan
JPMorgan lowered the firm’s price target on Qiagen (QGEN) to $45 from $60 and keeps an Overweight rating on the shares.
Qiagen price target lowered to $38 from $55 at Citi
Citi lowered the firm’s price target on Qiagen (QGEN) to $38 from $55 and keeps a Neutral rating on the shares.
Qiagen price target lowered to $38 from $44 at Barclays
Barclays analyst Luke Sergott lowered the firm’s price target on Qiagen (QGEN) to $38 from $44 and keeps an Equal Weight rating on the shares following the earnings report and
Qiagen upgraded to Outperform from Neutral at Baird
Baird upgraded Qiagen (QGEN) to Outperform from Neutral with a price target of $43, down from $53. The company’s Q1 results missed expectations driven by weaker QuantiFERON demand for immigration
Qiagen N.V. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, April 28, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Qiagen N.V. (NYSE: QGEN). The investigation focuses on Qiagen's executive...
Qiagen Transcript: Investor update
Q1 2026 delivered adjusted EPS in line with outlook, but sales missed targets due to lower QuantiFERON immigration testing and cautious U.S. life sciences demand. 2026 guidance was revised down for both sales and EPS, but strong growth is expected in H2 from new launches and efficiency gains.
Qiagen cuts FY26 EPS view to ‘at least’ $2.43 from ‘at least’ $2.50
Consensus $2.51. The company states: “QIAGEN (QGEN) has updated its full-year 2026 outlook for net sales growth of about 1-2% CER (previously at least 5% CER growth). Key factors include
Qiagen down 5% at $36.11 after Q1 pre-announcement, FY26 guidance cut
16:23 EDT Qiagen (QGEN) down 5% at $36.11 after Q1 pre-announcement, FY26 guidance cut
Qiagen reports Q1 preliminary EPS ‘at least’ 54c, consensus 54c
Reports Q1 preliminary revenue $492M, consensus $501.5M. “QIAGEN (QGEN) made important progress across many areas of the portfolio in the first quarter, led by solid sales growth in Sample technologie...
Qiagen sees Q2 EPS ‘at least’ 60c, consensus 62c
Sees Q2 revenue down 2% y/y, implying $523.3M, consensus $554.5M.
QIAGEN reports preliminary Q1 2026 results: achieves adjusted EPS outlook with mixed sales trends; updates full-year 2026 outlook
VENLO, the Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary results for the first quarter of 2026, continuing to deli...
Unusually active option classes on open April 27th
Unusual total active option classes on open include: Qiagen (QGEN), Petroleo Brasileiro (PBR/A), Sportradar Group (SRAD), Americas Silver (USAS), Organon and Co (OGN), Joby Aviation (JOBY), Qualcomm (...
QIAGEN to Showcase New Sample to Insight Solutions for Complex Oncology Applications at AACR 2026
GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it will showcase its oncology workflow applications at the American Assoc...
Qiagen expands into bloodstream infection syndromic testing
The company states: “QIAGEN (QGEN) announced its expansion into syndromic testing for bloodstream infections with the launch of the CE-IVDR-certified QIAstat-Dx BCID GPF Plus AMR Panel. The launch of ...
QIAGEN Expands Into Bloodstream Infection Syndromic Testing With New Rapid QIAstat-Dx Panel
HILDEN, Germany & VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its expansion into syndromic testing for bloodstream in...
Qiagen price target raised to EUR 44 from EUR 43 at Morgan Stanley
Morgan Stanley analyst Aisyah Noor raised the firm’s price target on Qiagen (QGEN) to EUR 44 from EUR 43 and keeps an Equal Weight rating on the shares. Published first
Qiagen downgraded to Equal Weight from Overweight at Barclays
Barclays downgraded Qiagen (QGEN) to Equal Weight from Overweight with a price target of $44, down from $58. The firm now sees the company’s takeout potential as less likely. Qiagen